Ardelyx (ARDX) PEG Ratio: History & Chart

Ardelyx, Inc.(ARDX)

Biotechnology · Waltham, MA

$3.34-0.06 (-1.62%)

Delayed quote: Oct 6, 2026, 9:45 AM EDT

About Ardelyx, Inc.

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.

Waltham, MA

489 employees

www.ardelyx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael G. Raab

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Ardelyx, Inc. (ARDX)	$823.84M	N/A	N/A	N/A	N/A
Alumis Inc. (ALMS)vs ›	$837.98M	N/A	N/A	N/A	N/A
InMode Ltd. (INMD)vs ›	$813.07M	1.16	0.85	0.47	0.33
Gyre Therapeutics, Inc. (GYRE)vs ›	$804.39M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$848.19M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$796.81M	N/A	N/A	N/A	N/A
Apnimed, Inc. (APMD)vs ›	$847.84M	N/A	N/A	N/A	N/A
Jade Biosciences, Inc. (JBIO)vs ›	$852.65M	N/A	N/A	N/A	N/A
AdaptHealth Corp. (AHCO)vs ›	$786.39M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$857.50M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Ardelyx, Inc. (ARDX)

$823.84M

N/A

Alumis Inc. (ALMS)vs ›

$837.98M

N/A

InMode Ltd. (INMD)vs ›

$813.07M

1.16

0.85

0.47

0.33

Gyre Therapeutics, Inc. (GYRE)vs ›

$804.39M

N/A

Monte Rosa Therapeutics, Inc. (GLUE)vs ›

$848.19M

N/A

Cytek Biosciences, Inc. (CTKB)vs ›

$796.81M

N/A

Apnimed, Inc. (APMD)vs ›

$847.84M

N/A

Jade Biosciences, Inc. (JBIO)vs ›

$852.65M

N/A

AdaptHealth Corp. (AHCO)vs ›

$786.39M

N/A

Beta Bionics, Inc. (BBNX)vs ›

$857.50M

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

ARDX PEG Ratio Metrics

ARDX Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics